Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) ligase binding moiety covalently linked to an ...

Representatives from four leading companies highlight emerging basic and clinical research that drives renewed optimism.

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...